D70.1 Agranulocytosis secondary to cancer chemotherapy

Name of the Condition

• Agranulocytosis secondary to cancer chemotherapy

Summary

Agranulocytosis secondary to cancer chemotherapy is a condition characterized by a severe reduction or absence of neutrophils, a type of white blood cell critical for fighting infections. This occurs as a direct result of chemotherapy treatment for cancer and increases the risk of bacterial and fungal infections. The condition is typically temporary and resolves once chemotherapy is completed or adjusted.

Causes

Agranulocytosis secondary to cancer chemotherapy is caused by the toxic effects of chemotherapy drugs on bone marrow, where neutrophils are produced. These drugs suppress bone marrow function, leading to a decrease in neutrophil production. The severity and duration of neutropenia depend on the specific chemotherapy regimen, dosage, and individual patient factors.

Risk Factors

• Type and intensity of chemotherapy regimen
• Prolonged or high-dose chemotherapy
• Pre-existing bone marrow disorders
• Advanced age
• Poor nutritional status
• Concurrent use of other myelosuppressive medications

Symptoms

• Fever and chills (signs of infection)
• Sore throat or mouth ulcers
• Skin infections or abscesses
• Respiratory infections (e.g., pneumonia)
• Fatigue or weakness
• Rapid or irregular heartbeat

Diagnosis

Diagnosis is confirmed through blood tests showing a significantly low neutrophil count (neutropenia). A complete blood count (CBC) with differential is typically performed to assess white blood cell levels. Additional tests, such as blood cultures or imaging, may be used to identify or rule out infections. The temporal relationship to chemotherapy administration is key to confirming the diagnosis.

Treatment Options

Treatment focuses on managing infections and supporting bone marrow recovery. This may include:

• Broad-spectrum antibiotics or antifungals to treat or prevent infections
• Granulocyte colony-stimulating factors (G-CSFs) to stimulate neutrophil production
• Adjusting or pausing chemotherapy to allow bone marrow recovery
• Supportive care, such as hydration and nutritional support

Prognosis and Follow-Up

Prognosis is generally favorable if infections are promptly treated and chemotherapy is managed appropriately. Neutrophil levels typically recover within weeks after chemotherapy completion or adjustment. Follow-up blood tests monitor neutrophil counts, and patients are advised to avoid exposure to infections during recovery.

Complications

• Severe or life-threatening infections (e.g., sepsis)
• Prolonged neutropenia leading to treatment delays
• Increased risk of other blood cell abnormalities
• Hospitalization for infection management

Lifestyle & Prevention

• Practice strict hand hygiene to reduce infection risk
• Avoid crowds or sick individuals during neutropenia
• Maintain good oral hygiene to prevent mouth infections
• Follow dietary guidelines to minimize foodborne infections
• Report any signs of infection (e.g., fever) immediately

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Fever (temperature ≥38.0°C or 100.4°F)
• Chills, sore throat, or mouth sores
• Unexplained fatigue or weakness
• Signs of infection (e.g., redness, swelling, pus)

Tips for Medical Coders

When coding D70.1, ensure documentation clearly links the agranulocytosis to cancer chemotherapy. Include details such as the specific chemotherapy regimen, timing of neutropenia relative to treatment, and any interventions (e.g., G-CSFs). Verify that the condition is not attributed to other causes (e.g., autoimmune disorders) to support accurate coding.